Abstract: A computer system compnses a processor (2), memory (4) and a plurality of devices (6, 8, 12), the processor (2) and the memory (4) being operable to effect the operation of a fault response processor (AFR), and a device driver (GRAPHICS, NETWORK, H2IO, IO2L, SERIAL) for each of the devices. The fault response processor (AFR) is operable to generate a model which represents the processor (2), the memory (4) and the devices (6, 8, 12) of the computer system and the inter-connection of the processor (2), memory (4) and the devices (GRAPHICS, NETWORK, H2IO, IO2L, SERIAL). The device driver (GRAPHICS, NETWORK, H2IO, IO2L, SERIAL) for each of the devices (6, 8, 12) is arranged, consequent upon a change of operational status of the device, to generate fault report data indicating whether the change of status was caused internally within the device or externally by another connected device. The devices of the computer system may be formed as a plurality of Field Replaceable Units (FRU).

Abstract: The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

Abstract: Polymeric drug formulations containing a non-releasing single-phase dispersion of a water-soluble drug in a water-insoluble tissue-compatible polymer matrix. Polymeric drug formulations are also disclosed containing a single-phase dispersion of a water-soluble drug and a water-insoluble tissue-compatible polymer matrix, and a second, phase-disrupting polymer that is non-miscible with the tissue-compatible polymer and is present in an amount sufficient to form phase-separated microdomains of the second polymer in the tissue-compatible polymer matrix, so that the release rate of the water-soluble drug from the tissue-compatible polymer matrix is related to the amount of the second polymer. Methods of preparing the polymeric drug formulations are also described, as well as methods for site-specific drug delivery utilizing the polymeric drug formulations.

Abstract: The present invention relates to novel antithrombotic variants of thrombin or fragments thereof that are capable of proteolytically activating protein C, but which are substantially free of fibrinogen cleavage activity. The present invention further relates to variant polypeptidess that may be cleaved to yield active thrombin variants. The present invention also relates to methods of inhibiting thrombus formation in an animal or human subject by delivering an antithrombotic variant thrombin of the present invention to the blood of the subject. The present invention relates also to methods that use the novel variant thrombins for determining the level of protein C activation in a blood sample, or the thrombogenic potential of a patient.

Abstract: The invention relates to the prophylactic and therapeutic treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents which reduce the number of circulating platelets to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

Abstract: The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

Abstract: The present invention relates to novel antithrombotic variants of thrombin or fragments thereof that are capable of proteolytically activating protein C, but which are substantially free of fibrinogen cleavage activity. The present invention further relates to variant polypeptidess that may be cleaved to yield active thrombin variants. The present invention also relates to methods of inhibiting thrombus formation in an animal or human subject by delivering an antithrombotic variant thrombin of the present invention to the blood of the subject. The present invention relates also to methods that use the novel variant thrombins for determining the level of protein C activation in a blood sample, or the thrombogenic potential of a patient.

Abstract: The present invention relates to novel antithrombotic variants of thrombin or fragments thereof that are capable of proteolytically activating protein C, but which are substantially free of fibrinogen cleavage activity. The present invention further relates to variant polypeptidess that may be cleaved to yield active thrombin variants. The present invention also relates to methods of inhibiting thrombus formation in an animal or human subject by delivering an antithrombotic variant thrombin of the present invention to the blood of the subject. The present invention relates also to methods that use the novel variant thrombins for determining the level of protein C activation in a blood sample, or the thrombogenic potential of a patient.

Abstract: The invention relates to the prophylactic and therapeutic treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents which reduce the number of circulating platelets to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

Abstract: A method of forming a polymeric drug formulation in which a water-soluble drug is blended with a water-insoluble tissue-compatible polymer that is miscible in the solid phase with the drug, and with a poly(alkylene oxide), in a solvent system capable of forming a homogeneous solution of the drug, the tissue-compatible polymer and the poly(alkylene oxide), after which the solution is added to a non-solvent for the drug, the tissue-compatible polymer and the poly(alkylene oxide), so that a microdomain-separated solid co-precipitate of the drug, the tissue-compatible polymer and the poly(alkylene oxide) is formed, wherein the poly(alkylene oxide) is blended in an amount effective to form phase-separated microdomains in said co-precipitate.

Abstract: A computer system comprises a processor (2), memory (4) and a plurality of devices (6, 8, 10, 12), the processor (2) and the memory (4) being operable to effect the operation of a fault response processor (AFR), and a device driver (GRAPHICS, NETWORK, H2IO, IO2L, SERIAL) for each of the devices. The fault response processor (AFR) is operable to generate a model (81) which represents the processor (2), the memory (4) and the devices (6, 8, 10, 12) of the computer system and the inter-connection of the processor (2), memory (4) and the devices (GRAPHICS, NETWORK, H2IO, IO2L, SERIAL). The device driver (GRAPHICS, NETWORK, H2IO, IO2L, SERIAL) for each of the devices (6, 8, 10, 12) is arranged, consequent upon a change of operational status of the device, to generate fault report data indicating whether the change of status was caused internally within the device or externally by another connected device. The devices of the computer system may be formed as a plurality of Field Replaceable Units (FRU).

Abstract: A device driver (GRAPHICS, NETWORK, H2IO, IO2L, SERIAL) for use in a computer system comprising a processor (P), memory (M) and a device (GRAPHICS, NETWORK, H2IO, IO2L, SERIAL) operatively coupled to the computer system the device driver being operable to control the device to monitor an operational status of the device, and consequent upon a change in the operational status to generate a fault report data indicating whether the change of status was caused internally within the device or externally by another connected device which caused the change of operational status to occur. The fault reports may also include an indication of the operational status of the device. Furthermore, if the fault report data indicates that the change of status was caused externally, the device driver may generate fault direction information indicative of an apparent direction on a connection between the device and the other device suspected as causing the indicated external fault.

Abstract: The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

Abstract: A live snapshot of a first storage that is logically subdivided into a plurality of blocks is generated in a running computer system a manner to minimise the impact on the running of the computer system. On initiating the snapshot, the content of a portion of the first storage that includes at least one block is copying to snapshot storage and a copied indication for each copied block is recording in a copy map. In response to any write request to a block for which no copied indication has been recorded in the copy map, the content of the block is copied to the snapshot storage, prior to writing to that block. A copied indication for the copied block is also recorded in the copy map. The content of other blocks for which no copied indication has been recorded in the copy map is successively copied to the snapshot storage. A copied indication for each copied block is also recorded in the copy map.

Abstract: The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

Abstract: Polymeric drug formulations containing a non-releasing single-phase dispersion of a water-soluble drug in a water-insoluble tissue-compatible polymer matrix. Polymeric drug formulations are also disclosed containing a single-phase dispersion of a water-soluble drug and a water-insoluble tissue-compatible polymer matrix, and a second, phase-disrupting polymer that is non-miscible with the tissue-compatible polymer and is present in an amount sufficient to form phase-separated microdomains of the second polymer in the tissue-compatible polymer matrix, so that the release rate of the water-soluble drug from the tissue-compatible polymer matrix is related to the amount of the second polymer. Methods of preparing the polymeric drug formulations are also described, as well as methods for site-specific drug delivery utilizing the polymeric drug formulations.

Abstract: A device for the local delivery of a substance into a natural tissue conduit in the mammalian body. The device provides a means for locally delivering a substance into the boundary layer of fluid flowing through the conduit without substantially disrupting the fluid flow therethrough. For example, an indwelling endovascular support device is provided for delivery of a substance locally to a targeted treatment area. Also provided are methods of locally delivering a substance into a natural tissue conduit in the mammalian body utilizing the device of the present invention.

Abstract: Polymeric drug formulations containing a non-releasing single-phase dispersion of a water-soluble drug in a water-insoluble tissue-compatible polymer matrix. Polymeric drug formulations are also disclosed containing a single-phase dispersion of a water-soluble drug and a water-insoluble tissue-compatible polymer matrix, and a second, phase-disrupting polymer that is non-miscible with the tissue-compatible polymer and is present in an amount sufficient to form phase-separated microdomains of the second polymer in the tissue-compatible polymer matrix, so that the release rate of the water-soluble drug from the tissue-compatible polymer matrix is related to the amount of the second polymer. Methods of preparing the polymeric drug formulations are also described, as well as methods for site-specific drug delivery utilizing the polymeric drug formulations.

Abstract: A device for the local delivery of a substance into a natural tissue conduit in the mammalian body. The device has a substance delivery segment which provides a means for locally delivering a substance into the boundary layer of fluid flowing through the conduit without disrupting the fluid flow therethrough. For example, an indwelling catheter is provided for endovascular delivery of a substance locally to a targeted treatment area. Also provided are methods of locally delivering a substance into a natural tissue conduit in the mammalian body utilizing the device of the present invention.

Abstract: A device for the local delivery of a substance into a natural tissue conduit in the mammalian body. The device has a substance delivery segment which provides a means for locally delivering a substance into the boundary layer of fluid flowing through the conduit without disrupting the fluid flow therethrough. For example, an indwelling catheter is provided for endovascular delivery of a substance locally to a targeted treatment area. Also provided are methods of locally delivering a substance into a natural tissue conduit in the mammalian body utilizing the device of the present invention.